Petros Grivas, Clinical Director of the Genitourinary Cancers Program at the University of Washington and Seattle Cancer Care Alliance, shared a post on X:
“Excellent talk by my colleague Lei Deng on NSCLC!
Huge progress with adjuvant OSI or alectinib based on EGFR or ALK alterations, respectively; important role of peri-op IO but do you need neoadj or adj or both?”
More posts featuring Petros Grivas.
